Navigation Links
Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial

ure studies with the FDA. We are hopeful that these results will enable us to move forward to a pivotal phase III study earlier than originally anticipated."

These results are important not only for the development and approval path for HyCAMP(TM) itself but they provide validation of the technology platform. The HyACT(TM) platform is an extremely flexible formulation technology as it can be used with virtually any intravenously administered anti-cancer treatment. We have successfully completed Phase I clinical studies on HyACT(TM) formulations of two other chemotherapy drugs, doxorubicin and 5- flurouracil. Encouraging preclinical data has also been obtained on a number of other cytotoxics. More recently, we have demonstrated in preclinical studies that HyACT(TM) can also be used to significantly enhance the efficacy of newer targeted antibody therapies such as Avastin(TM) and Erbitux(TM) In the case of generic drugs or drugs close to patent expiry, the HyACT(TM) formulation may provide a means for companies to differentiate their products from other competitors in the market place, and thereby build product value.

HyCAMP(TM) and the proprietary formulation technology, HyACT(TM), were obtained following the successful acquisition of Melbourne based oncology company Meditech Research Limited in 2006. "The Phase II clinical results provide proof of concept for the HyACT(TM) platform. We expect this technology to build substantial value for shareholders, not only with HyCAMP(TM), but with other oncology drugs as well" Dr Ramsdale said.

Before HyCAMP(TM) can be marketed in the US, the drug needs to successfully complete a Phase III study, and receive marketing approval from the US FDA.

Alchemia wishes to acknowledge the commitment and thank the patients who volunteered to participate in this trial, and to acknowledge and thank the investigators, study research personnel and nursing staff at the 10 clinical sites across Australia who looked a
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:9/17/2014)... , Sept. 17, 2014 BRIC Gynecological ... GlobalData,s new report, "BRIC Gynecological ... data on the BRIC Gynecological Devices market. The ... volume (in units) and average prices (in US ... (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization Devices ...
(Date:9/17/2014)... Sept. 17, 2014  Dr. Stephen Loyd , ... House today for National Recovery Month, stars in a ... released today. Consumer advocates were also joined by a ... out after losing her fiancée because of a preventable ... had a history of crack cocaine abuse. Proposition 46 ...
(Date:9/17/2014)... Bronstein, Gewirtz & Grossman, LLC is investigating ... of PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") ... advised to contact Peretz Bronstein or his ... info@bgandg.com or 212-697-6484. The investigation focuses ... violated federal securities laws. On September 16, ...
Breaking Medicine Technology:BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
... Virtual CME, LLC , a leading provider in ... of the industry,s first online, image based CME accredited ... of streaming video, 3D visualization cloud computing, and webinars, ... "Realizing that training in medical imaging is a ...
... Va., Aug. 26, 2011 Today, Medicomp Systems announced ... its new version of the powerful MEDCIN Engine®. ... that adapts to the unique clinical presentation of each ... for compliance and reimbursement. The MEDCIN Engine currently includes ...
Cached Medicine Technology:Medicomp Releases ICD-10-CM with New Version of the Powerful MEDCIN Engine® 2
(Date:9/17/2014)... Leading eco-friendly beauty brand , Lotus Moon, ... vegan and gluten-free Sugar Cane Fruit Mask. Their newest ... skincare testers were looking for. , “My goal ... that provided results, and I think I accomplished it,” ... Mask combines Willow bark (Salix Alba extract), a natural ...
(Date:9/17/2014)... 2014 The in vitro diagnostics (IVD) ... market, focusing on molecular diagnostics for conditions such as ... testing. The IVD market value is projected to be ... 2017. The major drivers of the market’s growth include ... is evidenced by the explosion for raid and minimally-invasive ...
(Date:9/17/2014)... (HealthDay News) -- Present-day Europeans are the descendants ... according to a new study. Previous ... and early European farmers. But, a new genetic ... also the descendants of Ancient North Eurasians. Nearly ... third ancestral group, researchers from Harvard Medical School ...
(Date:9/17/2014)... 17, 2014 (HealthDay News) -- Managing diabetes, quitting smoking, ... weight can reduce the risk for dementia -- even ... The World Alzheimer Report 2014, commissioned by Alzheimer,s Disease ... dementia by 50 percent. The study noted that obesity ... diabetes as well as high blood pressure. ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... and dieters who turn to artificial sweeteners to soothe ... favors, a new Israeli study suggests. Artificial sweeteners ... no calories, researchers found in human and mouse studies. ... alter the bacteria residing in the intestines in ways ...
Breaking Medicine News(10 mins):Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 3Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 2Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 3
... may benefit from HPV vaccine, study finds , TUESDAY, June ... for women aged 24 to 45 who aren,t already infected ... cancer and other cervical diseases. , That,s the finding from ... Bogota, Columbia, who noted that women,s rising age at first ...
... 2, 2009 Because bleeding from the reproductive tract ... women who exhibit menorrhagia, or excessive bleeding after their ... In order to address important issues related to the ... with bleeding disorders, a consensus conference was convened. Results ...
... use a new, cutting edge diagnostic technology to fight serious ... , WOBURN, Mass., and VEDBAEK, Denmark, June 2 AdvanDx ... Georgia has implemented AdvanDx,s PNA FISH(R) tests to identify bloodstream ... help their physicians, pharmacists and nurses improve care and outcomes ...
... Reporting Now Available Through CSC,s FirstPortfolio Offering , ... CSC ) today announced that it has ... to include fully integrated Medicare Secondary Payer (MSP) reporting ... of applications hosted and maintained by CSC. , ...
... Couple,s Struggle with Alzheimer,s , , WASHINGTONVILLE, N.Y., June 2 ... over 5 million Americans currently living with Alzheimer,s disease and the ... to announce the release of her book, "Released to the Angels: ... ). , , "Released to the Angels" is an ...
... 2 Rules-Based Medicine, Incorporated (RBM), the leading biomarker ... has joined the Company as vice president, clinical diagnostics. ... as RBM commercializes new biomarker-based diagnostic tests. ... biomarker assays for improved drug development, has programs to ...
Cached Medicine News:Health News:Cervical Cancer Vaccine Not Just for Teens 2Health News:Experts reach consensus on diagnosis and treatment of bleeding disorders in women 2Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 2Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 3Health News:CSC Offers Medicare Secondary Payer Reporting to Health Plans 2Health News:The Unexpected Gifts of Alzheimer's 2Health News:The Unexpected Gifts of Alzheimer's 3Health News:Rules-Based Medicine, Inc. Names Tony Barnes to Lead Expanding Diagnostics Business 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: